List of Almirall patents

Patents where

Current Assignee

Name

Almirall

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 7189741 Indolylpiperidine derivatives as antihistaminic and antiallergic agents	Patent 7189741 was granted and assigned to Almirall on March, 2007 by the United States Patent and Trademark Office.		Almirall	United States Patent and Trademark Office	7189741	March 13, 2007
‌ US Patent 7954492 Pharmaceutical powder cartridge, and inhaler equipped with same	Patent 7954492 was granted and assigned to Almirall on June, 2011 by the United States Patent and Trademark Office.		Almirall	United States Patent and Trademark Office	7954492	June 7, 2011
‌ US Patent 9907807 Topical pharmaceutical compositions	Patent 9907807 was granted and assigned to Almirall on March, 2018 by the United States Patent and Trademark Office.	Almirall	Almirall	United States Patent and Trademark Office	9907807	March 6, 2018
‌ US Patent 8258122 3-([1,2,4]triazolo[4,3-a]pyridin-7-yl)benzamide derivatives	Patent 8258122 was granted and assigned to Almirall on September, 2012 by the United States Patent and Trademark Office.		Almirall	United States Patent and Trademark Office	8258122	September 4, 2012
‌ US Patent 7893087 Quinuclidine derivatives and medicinal compositions containing the same	Patent 7893087 was granted and assigned to Almirall on February, 2011 by the United States Patent and Trademark Office.		Almirall	United States Patent and Trademark Office	7893087	February 22, 2011
‌ US Patent 9562039 Salts of 2-amino-1-hydroxyethyl-8-hydroxyquinolin-2(1H)-one derivatives having both β2 adrenergic receptor agonist and M3 muscarinic receptor antagonist activities	Patent 9562039 was granted and assigned to Almirall on February, 2017 by the United States Patent and Trademark Office.	Almirall	Almirall	United States Patent and Trademark Office	9562039	February 7, 2017
‌ US Patent 9315463 Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activities	Patent 9315463 was granted and assigned to Almirall on April, 2016 by the United States Patent and Trademark Office.		Almirall	United States Patent and Trademark Office	9315463	April 19, 2016
‌ US Patent 9388189 Pyrrolotriazinone derivatives as PI3K inhibitors	Patent 9388189 was granted and assigned to Almirall on July, 2016 by the United States Patent and Trademark Office.	Almirall	Almirall	United States Patent and Trademark Office	9388189	July 12, 2016
‌ US Patent 7776879 Quinuclidine carbamate derivatives and their use as M3 antagonists	Patent 7776879 was granted and assigned to Almirall on August, 2010 by the United States Patent and Trademark Office.		Almirall	United States Patent and Trademark Office	7776879	August 17, 2010
‌ US Patent 9340547 Pyrrolotriazinone derivatives as inhibitors P13K	Patent 9340547 was granted and assigned to Almirall on May, 2016 by the United States Patent and Trademark Office.		Almirall	United States Patent and Trademark Office	9340547	May 17, 2016
‌ US Patent 9579316 Salts of 2-amino-1-hydroxyethyl-8-hydroxyquinolin-2(1H)-one derivatives having both muscarinic receptor antagonist and β2 adrenergic receptor agonist activities	Patent 9579316 was granted and assigned to Almirall on February, 2017 by the United States Patent and Trademark Office.	Almirall	Almirall	United States Patent and Trademark Office	9579316	February 28, 2017
‌ US Patent 9643961 Cyclohexylamine derivatives having β2 adrenergic antagonist and M3 muscarinic antagonist activities	Patent 9643961 was granted and assigned to Almirall on May, 2017 by the United States Patent and Trademark Office.	Almirall	Almirall	United States Patent and Trademark Office	9643961	May 9, 2017
‌ US Patent 9518050 Cyclohexyl and quinuclidinyl carbamate derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activity	Patent 9518050 was granted and assigned to Almirall on December, 2016 by the United States Patent and Trademark Office.	Almirall	Almirall	United States Patent and Trademark Office	9518050	December 13, 2016
‌ US Patent 9346759 Polymorphic crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one, heminapadisytlate as agonist of the β2 adrenergic receptor	Patent 9346759 was granted and assigned to Almirall on May, 2016 by the United States Patent and Trademark Office.	Almirall	Almirall	United States Patent and Trademark Office	9346759	May 24, 2016
‌ US Patent 9233108 Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activities	Patent 9233108 was granted and assigned to Almirall on January, 2016 by the United States Patent and Trademark Office.	Almirall	Almirall	United States Patent and Trademark Office	9233108	January 12, 2016
‌ US Patent 10300072 Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activities	Patent 10300072 was granted and assigned to Almirall on May, 2019 by the United States Patent and Trademark Office.	Almirall	Almirall	United States Patent and Trademark Office	10300072	May 28, 2019
‌ US Patent 9549934 Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activities	Patent 9549934 was granted and assigned to Almirall on January, 2017 by the United States Patent and Trademark Office.	Almirall	Almirall	United States Patent and Trademark Office	9549934	January 24, 2017
‌ US Patent 9687478 Quinuclidine derivatives and medicinal compositions containing the same	Patent 9687478 was granted and assigned to Almirall on June, 2017 by the United States Patent and Trademark Office.	Almirall	Almirall	United States Patent and Trademark Office	9687478	June 27, 2017
‌ US Patent 8242177 Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the β2 adrenergic receptor	Patent 8242177 was granted and assigned to Almirall on August, 2012 by the United States Patent and Trademark Office.		Almirall	United States Patent and Trademark Office	8242177	August 14, 2012
‌ US Patent 9056100 Quinuclidine derivatives and medicinal compositions containing the same	Patent 9056100 was granted and assigned to Almirall on June, 2015 by the United States Patent and Trademark Office.	Almirall	Almirall	United States Patent and Trademark Office	9056100	June 16, 2015
‌ US Patent 10588895 Quinuclidine derivatives and medicinal compositions containing the same	Patent 10588895 was granted and assigned to Almirall on March, 2020 by the United States Patent and Trademark Office.	Almirall	Almirall	United States Patent and Trademark Office	10588895	March 17, 2020
‌ US Patent 9757383 Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activities	Patent 9757383 was granted and assigned to Almirall on September, 2017 by the United States Patent and Trademark Office.	Almirall	Almirall	United States Patent and Trademark Office	9757383	September 12, 2017
‌ US Patent 7964615 Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the β2 adrenergic receptor	Patent 7964615 was granted and assigned to Almirall on June, 2011 by the United States Patent and Trademark Office.		Almirall	United States Patent and Trademark Office	7964615	June 21, 2011
‌ US Patent 9333195 Quinuclidine derivatives and medicinal compositions containing the same	Patent 9333195 was granted and assigned to Almirall on May, 2016 by the United States Patent and Trademark Office.	Almirall	Almirall	United States Patent and Trademark Office	9333195	May 10, 2016
‌ US Patent RE46417 Quinuclidine derivatives and their use as muscarinic M3 receptor ligands	Patent RE46417 was granted and assigned to Almirall on May, 2017 by the United States Patent and Trademark Office.		Almirall	United States Patent and Trademark Office	RE46417	May 30, 2017

Results per page:

59 results

0 selected

59 results

0 selected